deaths (OS)progression or deaths (PFS)RFS/DFS

mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population

versus Standard of Care (SoC)
nivolumab alone vs. Standard of Care (SoC) 1 certainty unassessable-5% certainty unassessable+3%-

mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant